American Cancer Society; and Emory University, Atlanta, GA, USA.
J Oncol Pract. 2013 Jan;9(1):27-33. doi: 10.1200/JOP.2012.000627.
Although the number of medical oncologists (MOs) has steadily increased over time, and adjuvant chemotherapy provides significant survival benefit for patients with stage III colon cancer, many patients still do not receive chemotherapy. Uneven geographic distribution of MOs may contribute to decreasing access to cancer care. This study explored the association of MO availability by hospital service area (HSA) of patient residence and access to chemotherapy treatment.
Using the linked SEER-Medicare database, the study identified 9,262 patients who were age ≥66 years and underwent colectomy for stage III colon cancer diagnosed from 2000 to 2005. MOs were identified by physician specialty codes. HSAs are geographic areas that are relatively self-contained with respect to routine hospital care. Multivariate logistic regression was used to investigate the association between MO availability by HSA of patient residence and initiation of chemotherapy.
Within 3 months after colectomy, 5,622 patients (60.7%) initiated chemotherapy. Adjusting for clinical and patient characteristics, patients residing in an HSA with ≥ one MO had an increased likelihood of initiating chemotherapy within 3 months after colectomy compared with those living in areas with no MOs (one to two MOs: OR, 1.451 [P < .01]; three to eight MOs: OR, 1.497 [P < .01]; ≥ nine MOs: OR, 1.322 [P < .01]).
Results suggest that the availability of ≥ one MO within the HSA in which a patient resides was associated with greater access to chemotherapy after surgery.
尽管医学肿瘤学家(MO)的数量随着时间的推移稳步增加,并且辅助化疗为 III 期结肠癌患者提供了显著的生存获益,但仍有许多患者未接受化疗。MO 分布不均可能导致癌症治疗的可及性降低。本研究探讨了患者居住地的医院服务区(HSA)中 MO 可用性与接受化疗治疗之间的关联。
本研究使用 SEER-Medicare 数据库,确定了 9262 名年龄≥66 岁且在 2000 年至 2005 年间接受 III 期结肠癌切除术的患者。通过医生专业代码确定 MO。HSA 是相对于常规医院护理相对自成一体的地理区域。采用多变量逻辑回归分析患者居住地 HSA 中 MO 可用性与化疗起始之间的关联。
在结肠切除术后 3 个月内,有 5622 名患者(60.7%)开始接受化疗。在调整了临床和患者特征后,与居住在没有 MO 的地区的患者相比,居住在有≥1 名 MO 的 HSA 中的患者在结肠切除术后 3 个月内开始化疗的可能性更高(有 1 至 2 名 MO:OR,1.451[P<0.01];有 3 至 8 名 MO:OR,1.497[P<0.01];有≥9 名 MO:OR,1.322[P<0.01])。
结果表明,患者居住地 HSA 中有≥1 名 MO 的可用性与手术后化疗的可及性增加有关。